Literature DB >> 25411487

Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.

Gretchen M Thomsen1, Genevieve Gowing1, Jessica Latter1, Maximus Chen1, Jean-Philippe Vit2, Kevin Staggenborg1, Pablo Avalos1, Mor Alkaslasi1, Laura Ferraiuolo3, Shibi Likhite3, Brian K Kaspar4, Clive N Svendsen5.   

Abstract

Sporadic amyotrophic lateral sclerosis (ALS) is a fatal disease with unknown etiology, characterized by a progressive loss of motor neurons leading to paralysis and death typically within 3-5 years of onset. Recently, there has been remarkable progress in understanding inherited forms of ALS in which well defined mutations are known to cause the disease. Rodent models in which the superoxide dismutase-1 (SOD1) mutation is overexpressed recapitulate hallmark signs of ALS in patients. Early anatomical changes in mouse models of fALS are seen in the neuromuscular junctions (NMJs) and lower motor neurons, and selective reduction of toxic mutant SOD1 in the spinal cord and muscle of these models has beneficial effects. Therefore, much of ALS research has focused on spinal motor neuron and NMJ aspects of the disease. Here we show that, in the SOD1(G93A) rat model of ALS, spinal motor neuron loss occurs presymptomatically and before degeneration of ventral root axons and denervation of NMJs. Although overt cell death of corticospinal motor neurons does not occur until disease endpoint, we wanted to establish whether the upper motor neuron might still play a critical role in disease progression. Surprisingly, the knockdown of mutant SOD1 in only the motor cortex of presymptomatic SOD1(G93A) rats through targeted delivery of AAV9-SOD1-shRNA resulted in a significant delay of disease onset, expansion of lifespan, enhanced survival of spinal motor neurons, and maintenance of NMJs. This datum suggests an early dysfunction and thus an important role of the upper motor neuron in this animal model of ALS and perhaps patients with the disease.
Copyright © 2014 the authors 0270-6474/14/3415587-14$15.00/0.

Entities:  

Keywords:  ALS; RNAi; SOD1; amyotrophic lateral sclerosis; motor neuron disease; neurodegenerative disorder

Mesh:

Substances:

Year:  2014        PMID: 25411487      PMCID: PMC4298650          DOI: 10.1523/JNEUROSCI.2037-14.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

Review 1.  Axon guidance proteins: novel therapeutic targets for ALS?

Authors:  Ewoud R E Schmidt; R Jeroen Pasterkamp; Leonard H van den Berg
Journal:  Prog Neurobiol       Date:  2009-06-10       Impact factor: 11.685

2.  The seeds of neurodegeneration: prion-like spreading in ALS.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

3.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

4.  Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo.

Authors:  Paola Arlotta; Bradley J Molyneaux; Jinhui Chen; Jun Inoue; Ryo Kominami; Jeffrey D Macklis
Journal:  Neuron       Date:  2005-01-20       Impact factor: 17.173

5.  New considerations in the design of clinical trials for amyotrophic lateral sclerosis.

Authors:  James D Berry; Merit E Cudkowicz
Journal:  Clin Investig (Lond)       Date:  2011-10

6.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

Review 7.  Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Expert Opin Investig Drugs       Date:  2014-06-26       Impact factor: 6.206

Review 8.  Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons.

Authors:  S M Chou; F H Norris
Journal:  Muscle Nerve       Date:  1993-08       Impact factor: 3.217

9.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons.

Authors:  Brian J Wainger; Evangelos Kiskinis; Cassidy Mellin; Ole Wiskow; Steve S W Han; Jackson Sandoe; Numa P Perez; Luis A Williams; Seungkyu Lee; Gabriella Boulting; James D Berry; Robert H Brown; Merit E Cudkowicz; Bruce P Bean; Kevin Eggan; Clifford J Woolf
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

10.  SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter.

Authors:  D Trotti; A Rolfs; N C Danbolt; R H Brown; M A Hediger
Journal:  Nat Neurosci       Date:  1999-05       Impact factor: 24.884

View more
  54 in total

Review 1.  New perspectives on amyotrophic lateral sclerosis: the role of glial cells at the neuromuscular junction.

Authors:  Danielle Arbour; Christine Vande Velde; Richard Robitaille
Journal:  J Physiol       Date:  2016-12-01       Impact factor: 5.182

2.  Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.

Authors:  Paul N Valdmanis; Mark A Kay
Journal:  Hum Gene Ther       Date:  2017-01-10       Impact factor: 5.695

Review 3.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

Review 4.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

5.  Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model.

Authors:  Lorelei Stoica; Sophia H Todeasa; Gabriela Toro Cabrera; Johnny S Salameh; Mai K ElMallah; Christian Mueller; Robert H Brown; Miguel Sena-Esteves
Journal:  Ann Neurol       Date:  2016-03-11       Impact factor: 10.422

6.  Treatment of a Mouse Model of ALS by In Vivo Base Editing.

Authors:  Colin K W Lim; Michael Gapinske; Alexandra K Brooks; Wendy S Woods; Jackson E Powell; M Alejandra Zeballos C; Jackson Winter; Pablo Perez-Pinera; Thomas Gaj
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

7.  Effects of Tongue Force Training on Bulbar Motor Function in the Female SOD1-G93A Rat Model of Amyotrophic Lateral Sclerosis.

Authors:  Delin Ma; Jeffrey M Shuler; Aishwarya Kumar; Quincy R Stanford; Sudheer Tungtur; Hiroshi Nishimune; John A Stanford
Journal:  Neurorehabil Neural Repair       Date:  2016-09-24       Impact factor: 3.919

Review 8.  Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.

Authors:  Maria Sara Cipolat Mis; Simona Brajkovic; Francesco Tafuri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2016-06-28       Impact factor: 5.590

Review 9.  Modeling ALS with motor neurons derived from human induced pluripotent stem cells.

Authors:  Samuel Sances; Lucie I Bruijn; Siddharthan Chandran; Kevin Eggan; Ritchie Ho; Joseph R Klim; Matt R Livesey; Emily Lowry; Jeffrey D Macklis; David Rushton; Cameron Sadegh; Dhruv Sareen; Hynek Wichterle; Su-Chun Zhang; Clive N Svendsen
Journal:  Nat Neurosci       Date:  2016-04       Impact factor: 24.884

Review 10.  Incorporating upper motor neuron health in ALS drug discovery.

Authors:  Ina Dervishi; P Hande Ozdinler
Journal:  Drug Discov Today       Date:  2018-01-10       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.